Summary

An oral Janus kinase inhibitor, in combination with methotrexate, led to significant improvements in a treatment-refractory rheumatoid arthritis population with no significant safety concerns. This article discusses the Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 2 Doses of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate With Inadequate Response to TNF Inhibitors study [ORAL Sync; NCT00960440].